Potentially curable pancreatic cancer: American society of clinical oncology clinical practice guideline

Alok A. Khorana, Pamela B. Mangu, Jordan Berlin, Anitra Engebretson, Theodore S. Hong, Anirban Maitra, Supriya G. Mohile, Matthew Mumber, Richard Schulick, Marc Shapiro, Susan Urba, Herbert J. Zeh, Matthew H.G. Katz

Research output: Contribution to journalArticle

119 Citations (Scopus)

Abstract

Purpose To provide evidence-based recommendations to oncologists and others on potentially curative therapy for patients with localized pancreatic cancer. Methods ASCO convened a panel of medical oncology, radiation oncology, surgical oncology, palliative care, and advocacy experts and conducted a systematic review of literature from January 2002 to June 2015.Outcomes included overall survival, disease-free survival, progression-free survival, and adverse events. Results Nine randomized controlled trials met the systematic review criteria. Recommendations A multiphase computed tomography scan of the abdomen and pelvis or magnetic resonance imaging should be performed for all patients to assess the anatomic relationships of the primary tumor and for the presence of intra-abdominal metastases. Baseline performance status, comorbidity profile, and goals of care should be evaluated and established. Primary surgical resection is recommended for all patients who have no metastases, appropriate performance and comorbidity profiles, and no radiographic interface between primary tumor and mesenteric vasculature. Preoperative therapy is recommended for patients who meet specific characteristics. All patients with resected pancreatic cancer who did not receive preoperative therapy should be offered 6 months of adjuvant chemotherapy in the absence of contraindications. Adjuvant chemoradiation may be offered to patients who did not receive preoperative therapy with microscopically positive margins (R1) after resection and/or who had node-positive disease after completion of 4 to 6 months of systemic adjuvant chemotherapy. Patients should have a full assessment of symptoms, psychological status, and social supports and should receive palliative care early. Patients who have completed treatment and have no evidence of disease should be monitored.

Original languageEnglish (US)
Pages (from-to)2541-2556
Number of pages16
JournalJournal of Clinical Oncology
Volume34
Issue number21
DOIs
StatePublished - Jul 20 2016
Externally publishedYes

Fingerprint

Medical Oncology
Pancreatic Neoplasms
Practice Guidelines
Adjuvant Chemotherapy
Palliative Care
Disease-Free Survival
Comorbidity
Patient Care Planning
Neoplasm Metastasis
Therapeutics
Radiation Oncology
Symptom Assessment
Pelvis
Social Support
Abdomen
Neoplasms
Randomized Controlled Trials
Tomography
Magnetic Resonance Imaging
Psychology

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Khorana, A. A., Mangu, P. B., Berlin, J., Engebretson, A., Hong, T. S., Maitra, A., ... Katz, M. H. G. (2016). Potentially curable pancreatic cancer: American society of clinical oncology clinical practice guideline. Journal of Clinical Oncology, 34(21), 2541-2556. https://doi.org/10.1200/JCO.2016.67.5553

Potentially curable pancreatic cancer : American society of clinical oncology clinical practice guideline. / Khorana, Alok A.; Mangu, Pamela B.; Berlin, Jordan; Engebretson, Anitra; Hong, Theodore S.; Maitra, Anirban; Mohile, Supriya G.; Mumber, Matthew; Schulick, Richard; Shapiro, Marc; Urba, Susan; Zeh, Herbert J.; Katz, Matthew H.G.

In: Journal of Clinical Oncology, Vol. 34, No. 21, 20.07.2016, p. 2541-2556.

Research output: Contribution to journalArticle

Khorana, AA, Mangu, PB, Berlin, J, Engebretson, A, Hong, TS, Maitra, A, Mohile, SG, Mumber, M, Schulick, R, Shapiro, M, Urba, S, Zeh, HJ & Katz, MHG 2016, 'Potentially curable pancreatic cancer: American society of clinical oncology clinical practice guideline', Journal of Clinical Oncology, vol. 34, no. 21, pp. 2541-2556. https://doi.org/10.1200/JCO.2016.67.5553
Khorana, Alok A. ; Mangu, Pamela B. ; Berlin, Jordan ; Engebretson, Anitra ; Hong, Theodore S. ; Maitra, Anirban ; Mohile, Supriya G. ; Mumber, Matthew ; Schulick, Richard ; Shapiro, Marc ; Urba, Susan ; Zeh, Herbert J. ; Katz, Matthew H.G. / Potentially curable pancreatic cancer : American society of clinical oncology clinical practice guideline. In: Journal of Clinical Oncology. 2016 ; Vol. 34, No. 21. pp. 2541-2556.
@article{9f7d3193a41742be9bca383b3b3ec272,
title = "Potentially curable pancreatic cancer: American society of clinical oncology clinical practice guideline",
abstract = "Purpose To provide evidence-based recommendations to oncologists and others on potentially curative therapy for patients with localized pancreatic cancer. Methods ASCO convened a panel of medical oncology, radiation oncology, surgical oncology, palliative care, and advocacy experts and conducted a systematic review of literature from January 2002 to June 2015.Outcomes included overall survival, disease-free survival, progression-free survival, and adverse events. Results Nine randomized controlled trials met the systematic review criteria. Recommendations A multiphase computed tomography scan of the abdomen and pelvis or magnetic resonance imaging should be performed for all patients to assess the anatomic relationships of the primary tumor and for the presence of intra-abdominal metastases. Baseline performance status, comorbidity profile, and goals of care should be evaluated and established. Primary surgical resection is recommended for all patients who have no metastases, appropriate performance and comorbidity profiles, and no radiographic interface between primary tumor and mesenteric vasculature. Preoperative therapy is recommended for patients who meet specific characteristics. All patients with resected pancreatic cancer who did not receive preoperative therapy should be offered 6 months of adjuvant chemotherapy in the absence of contraindications. Adjuvant chemoradiation may be offered to patients who did not receive preoperative therapy with microscopically positive margins (R1) after resection and/or who had node-positive disease after completion of 4 to 6 months of systemic adjuvant chemotherapy. Patients should have a full assessment of symptoms, psychological status, and social supports and should receive palliative care early. Patients who have completed treatment and have no evidence of disease should be monitored.",
author = "Khorana, {Alok A.} and Mangu, {Pamela B.} and Jordan Berlin and Anitra Engebretson and Hong, {Theodore S.} and Anirban Maitra and Mohile, {Supriya G.} and Matthew Mumber and Richard Schulick and Marc Shapiro and Susan Urba and Zeh, {Herbert J.} and Katz, {Matthew H.G.}",
year = "2016",
month = "7",
day = "20",
doi = "10.1200/JCO.2016.67.5553",
language = "English (US)",
volume = "34",
pages = "2541--2556",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "21",

}

TY - JOUR

T1 - Potentially curable pancreatic cancer

T2 - American society of clinical oncology clinical practice guideline

AU - Khorana, Alok A.

AU - Mangu, Pamela B.

AU - Berlin, Jordan

AU - Engebretson, Anitra

AU - Hong, Theodore S.

AU - Maitra, Anirban

AU - Mohile, Supriya G.

AU - Mumber, Matthew

AU - Schulick, Richard

AU - Shapiro, Marc

AU - Urba, Susan

AU - Zeh, Herbert J.

AU - Katz, Matthew H.G.

PY - 2016/7/20

Y1 - 2016/7/20

N2 - Purpose To provide evidence-based recommendations to oncologists and others on potentially curative therapy for patients with localized pancreatic cancer. Methods ASCO convened a panel of medical oncology, radiation oncology, surgical oncology, palliative care, and advocacy experts and conducted a systematic review of literature from January 2002 to June 2015.Outcomes included overall survival, disease-free survival, progression-free survival, and adverse events. Results Nine randomized controlled trials met the systematic review criteria. Recommendations A multiphase computed tomography scan of the abdomen and pelvis or magnetic resonance imaging should be performed for all patients to assess the anatomic relationships of the primary tumor and for the presence of intra-abdominal metastases. Baseline performance status, comorbidity profile, and goals of care should be evaluated and established. Primary surgical resection is recommended for all patients who have no metastases, appropriate performance and comorbidity profiles, and no radiographic interface between primary tumor and mesenteric vasculature. Preoperative therapy is recommended for patients who meet specific characteristics. All patients with resected pancreatic cancer who did not receive preoperative therapy should be offered 6 months of adjuvant chemotherapy in the absence of contraindications. Adjuvant chemoradiation may be offered to patients who did not receive preoperative therapy with microscopically positive margins (R1) after resection and/or who had node-positive disease after completion of 4 to 6 months of systemic adjuvant chemotherapy. Patients should have a full assessment of symptoms, psychological status, and social supports and should receive palliative care early. Patients who have completed treatment and have no evidence of disease should be monitored.

AB - Purpose To provide evidence-based recommendations to oncologists and others on potentially curative therapy for patients with localized pancreatic cancer. Methods ASCO convened a panel of medical oncology, radiation oncology, surgical oncology, palliative care, and advocacy experts and conducted a systematic review of literature from January 2002 to June 2015.Outcomes included overall survival, disease-free survival, progression-free survival, and adverse events. Results Nine randomized controlled trials met the systematic review criteria. Recommendations A multiphase computed tomography scan of the abdomen and pelvis or magnetic resonance imaging should be performed for all patients to assess the anatomic relationships of the primary tumor and for the presence of intra-abdominal metastases. Baseline performance status, comorbidity profile, and goals of care should be evaluated and established. Primary surgical resection is recommended for all patients who have no metastases, appropriate performance and comorbidity profiles, and no radiographic interface between primary tumor and mesenteric vasculature. Preoperative therapy is recommended for patients who meet specific characteristics. All patients with resected pancreatic cancer who did not receive preoperative therapy should be offered 6 months of adjuvant chemotherapy in the absence of contraindications. Adjuvant chemoradiation may be offered to patients who did not receive preoperative therapy with microscopically positive margins (R1) after resection and/or who had node-positive disease after completion of 4 to 6 months of systemic adjuvant chemotherapy. Patients should have a full assessment of symptoms, psychological status, and social supports and should receive palliative care early. Patients who have completed treatment and have no evidence of disease should be monitored.

UR - http://www.scopus.com/inward/record.url?scp=84978857986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978857986&partnerID=8YFLogxK

U2 - 10.1200/JCO.2016.67.5553

DO - 10.1200/JCO.2016.67.5553

M3 - Article

C2 - 27247221

AN - SCOPUS:84978857986

VL - 34

SP - 2541

EP - 2556

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 21

ER -